Century Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Brent Pfeiffenberger
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 1.5% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Jun 20Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$130m |
| Jun 30 2024 | n/a | n/a | -US$131m |
| Mar 31 2024 | n/a | n/a | -US$133m |
| Dec 31 2023 | US$3m | US$50k | -US$137m |
Compensation vs Market: Brent's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.
CEO
Brent Pfeiffenberger
less than a year
Tenure
US$3,235,011
Compensation
Mr. Brent Pfeiffenberger, Pharm D., MBA, has been Chief Executive Officer and Director of Century Therapeutics, Inc. since December 04, 2023. He served as Chief Operating Officer at Neogene Therapeutics, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.24m | no data | |
| COO & Head of Early Development | 3.6yrs | US$1.71m | 0.10% $ 107.3k | |
| Chief Technology & Manufacturing Officer | less than a year | US$2.59m | 0.40% $ 426.2k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | 0.17% $ 182.4k | |
| Senior VP of General Counsel | no data | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Senior VP of Cell Engineering | 1.5yrs | no data | no data | |
| Senior VP & Head of Clinical Development | 1.8yrs | no data | no data | |
| SVP, Head of Corporate Affairs & Strategy | no data | no data | no data | |
| Senior VP of Finance & Operations and Secretary | no data | no data | 0.33% $ 344.4k |
0.9yrs
Average Tenure
56yo
Average Age
Experienced Management: IPSC's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.24m | no data | |
| Independent Director | 3.8yrs | US$170.65k | 0.12% $ 122.7k | |
| Independent Chairman of the Board | 5.8yrs | US$197.40k | 0.58% $ 613.0k | |
| Independent Director | 2.2yrs | US$159.40k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$161.90k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$169.65k | 0.0059% $ 6.2k | |
| Independent Director | 3.8yrs | US$168.40k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$165.90k | 0% $ 0 |
3.5yrs
Average Tenure
60.5yo
Average Age
Experienced Board: IPSC's board of directors are considered experienced (3.5 years average tenure).